These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 3083555)

  • 1. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
    Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
    J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin for patients who have failed on thiotepa. The National Bladder Cancer Group.
    Koontz WW; Heney NM; Soloway MS; Kluskens L; Hazra TA; Trump DL; Barton B
    Urology; 1985 Oct; 26(4 Suppl):30-1. PubMed ID: 3931326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
    Zincke H; Benson RC; Hilton JF; Taylor WF
    J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
    Soloway MS; Jordan AM; Murphy WM
    Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined thiotepa and mitomycin C instillation therapy for low-grade superficial bladder tumor.
    Hu KN; Kim A; Khan AS; Soroff H; Gonder M
    Cancer; 1985 Apr; 55(8):1654-8. PubMed ID: 3156664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
    Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
    J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
    Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
    J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severely contracted bladder following intravesical mitomycin C therapy.
    Wajsman Z; McGill W; Englander L; Huben RP; Pontes JE
    J Urol; 1983 Aug; 130(2):340-1. PubMed ID: 6410085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
    Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
    Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
    Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
    J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times.
    Giesbers AA; Van Helsdingen PJ; Kramer AE
    Br J Urol; 1989 Feb; 63(2):176-9. PubMed ID: 2495144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
    Heney NM
    Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
    Soloway MS
    Urol Clin North Am; 1984 Nov; 11(4):623-35. PubMed ID: 6438857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive intravesical chemotherapy in the treatment of flat carcinoma in situ: is it safe?
    Droller MJ; Walsh PC
    J Urol; 1985 Dec; 134(6):1115-7. PubMed ID: 3932686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
    Baker WC; Russo MA; deVere White RW
    Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction and overview of intravesical therapy for superficial bladder cancer.
    Soloway MS
    Urology; 1988 Mar; 31(3 Suppl):5-16. PubMed ID: 3126593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
    Drago PC; Badalament RA; Lucas J; Drago JR
    J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.